One-year outcome of bevacizumab therapy for chronic macular edema in central and branch retinal vein occlusions in real-world clinical practice in the UK

Figures & data

Table 1 Demographic and baseline characteristics

	CRVO (n=56)	BRVO (n=100)
Mean age, years (SD; range)	69 (12.2; 34–87)	71 (11.05; 43–94)
Sex, male/female	26/30	51/49
Mean number of injections in 1 year (mode, range)	4.2 (3; 1–9)	3.3 (3; 1–9)
Loading frequency 1:2:3	13:9:34	20:21:59

Abbreviations: CRVO, central retinal vein occlusion; BRVO, branch retinal vein occlusion; SD, standard deviation.

Table 2 Baseline and changes in vision and central retinal thickness with bevacizumab therapy

	CRVO group	BRVO group
Visual changes in logMAR (Snellen equivalent), compared with baseline
Baseline median VA [IQR]	0.78 (6/36) [0.48–1.22]	0.60 (6/24) [0.30–0.78]
Median VA post-loading [IQR]	0.69 (6/30) [0.18–1.0], P=0.03	0.48 (6/18) [0.30–0.70], P<0.001
Median VA at 12 months [IQR]	0.78 (6/36) [0.30–1.30], P=0.166	0.54 (6/20) [0.30–0.78], P=0.058
Three-line visual improvement at 12 months	30%	24%
One-line visual improvement at 12 months	44%	51%
CRT changes (μm) versus baseline
Baseline median CRT [IQR]	449 [388–553]	411 [357–501]
Median CRT [IQR] post-loading	287 [237–402], P<0.001	309 [260–437], P<0.001
Median CRT [IQR] at 12 months	278 [229–495], P<0.001	335 [261–447], P<0.001

Abbreviations: CRVO, central retinal vein occlusion; BRVO, branch retinal vein occlusion; VA, visual acuity; IQR, interquartile range (statistical analysis using Wilcoxon signed-rank test); CRT, central retinal thickness; logMAR, logarithm of the minimum angle of resolution.

Table 3 Preexisting risk factors, previous therapy, and adverse effects

	CRVO (n=56)	BRVO (n=100)
Recorded risk factors
Known cardiovascular risks	26 (46%)	36 (36%)
Referral to cardiovascular assessment (recorded in notes)	10 (18%)	10 (10%)
Known glaucoma/ocular hypertension	20 (36%)	14 (14%)
Chronicity indication
Had previous laser therapy	25 (45%)	36 (36%)
Had previous triamcinolone	11 (20%)	2 (2%)
Adverse effects
Raised IOP	2 (4%) 1(rubeotic glaucoma)	5 (5%)
Corneal abrasion	0	2 (2%)
Endophthalmitis	0	0

Abbreviations: CRVO, central retinal vein occlusion; BRVO, branch retinal vein occlusion; IOP, intraocular pressure.